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A possible acute, analgesic effect of oxytocin was inves-
tigated at the beginning of the study. After baseline evalua-
tion, patients self-administered oxytocin (20-IU) or placebo 
and waited for 1 h, when central oxytocin levels achieve 
the highest values [4–6]. Then, the severity of actual pain 
was investigated, but no difference was found (placebo 
43.3 ± 10.6; oxytocin 47.2 ± 16.2, p = 0.15, t test). The 
acute effects of 40-IU was not examined as patients started 
with this dose after 1 week of a 20-IU treatment, and this 
evaluation would not be a reliable measure of 40-IU acute 
effects.
Under our experimental conditions, chronic treatments 
with 20-IU or 40-IU did not reduce the severity of pain. 
We concluded that higher doses or long periods of treat-
ment might unravel an analgesic effect of oxytocin. Recent 
studies found that 24-IU of oxytocin (1) induced stronger 
effects than 48-IU in cortisol response to intense exercise 
[7] and (2) was effective in reducing obesity if administered 
4 times daily for 8 weeks [8]. Accordingly, the ideal sched-
ule seems to be constituted by more frequent daily adminis-
trations of lower doses, and for longer periods of time than 
those used in our studies (e.g., 24-IU, 4 times daily for at 
least 8 weeks rather than 40-IU twice daily for 3 weeks).
Despite the large body of preclinical evidence suggest-
ing an analgesic effect of oxytocin, the number of clinical 
studies is scarce. A recent review [9] reported that only five 
studies investigated this effect: among these, three studies 
found positive effects [10–12], one promising results [13], 
and one inconclusive results [14]. Recently, two additional 
clinical studies found opposite results [2, 15]. The differ-
ence between results may be due, at least in part, to the dif-
ferent patient samples (fibromyalgic patients vs. healthy 
adults) and methodological procedures (chronic vs. acute 
treatment; chronic unresponsive vs. acute cold pressor 
pain).
We read with interest the letter of Drs. Rash and Campbell 
[1] and are grateful to them for the opportunity to provide 
additional information to our short communication [2].
Regarding the procedure of the administration, the rec-
ommendations suggested by Guastella and colleagues were 
adopted [3]. During the first week, the dose was equal to 5 
puffs (20-IU) twice a day, then, to 10 puffs (40-IU) twice 
a day. The composition of the oxytocin and placebo nasal 
sprays was identical, except for the hormone. It is difficult 
to determine what influence the expectation of effects had 
on our results, as no data were collected on expectations. 
However, the lack of differences between the groups sug-
gests that oxytocin did not enhance placebo analgesia in 
our experimental conditions.
Our study was aimed at investigating the possible effec-
tiveness of chronic treatment in reducing the severity of 
pain. Accordingly, medications were self-administered by 
participants, twice daily, with a 12-h interval, for 3 weeks. 
patients registered the severity of pain at the end of the day, 
regardless of the time of the administration. At each weekly 
visit, the experimenter registered the severity of pain, 
regardless of the time of administration.
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Although the number of patients would have needed to 
be higher to detect small effects of oxytocin, this number 
was justified by the need to investigate whether oxytocin 
was safe in these patients, also affected by mental comor-
bidity and undergoing a complex pharmacotherapy. Our 
aims comprised not only the effectiveness but also the 
safety of oxytocin.
Further clinical studies are needed to improve our 
knowledge on the analgesic effects of oxytocin using dif-
ferent typologies of participants (health adults and patients 
with acute or chronic pain), methodological procedures 
(spontaneous and induced pain), and treatments (acute and 
chronic treatment; lower and higher doses; number of daily 
administrations).
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